We provide you with 20 years of free, institutional-grade data for LXEO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LXEO. Explore the full financial landscape of LXEO stock.
| Reported Date | CIK | Ticker | Type |
|---|
Lexeo Therapeutics, Inc.(NASDAQ:LXEO) 
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t...
Website: https://www.lexeotx.com/
Founded: 2017
IPO Price: $11 (Nov 13, 2023)
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about LXEO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.